Pre-Exposure Prophylaxis PrEP

More documents

Recommendations

Info

Last updated March 27, 2012;last reviewed ed March 27, 2012 Last updated d Sep 30, 2005
Last updated Jan 21, 2005© World Health Organization2007
Page 1 and 2: Narin Hiransuthikul MD, PhDDep. Pre
Page 3 and 4: THAILANDAdult (15-49 years) HIV Pre
Page 5 and 6: December 2009
Page 7 and 8: ้วิธีการต่า
Page 9 and 10: ่่้การใช้ยา
Page 11 and 12: • The ongoing use of one or two a
Page 14: Miller CJ, et al. J Virology 2005 :
Page 17 and 18: WhyTenofovirand/orEmtricitabine?
Page 19 and 20: Tenofovir (Viread) for PrEP• Nucl
Page 21 and 22: เพร็พแบบกินOr
Page 23 and 24: ีื่การศึกษา
Page 25 and 26: ความสัมพันธ
Page 27 and 28: ความท้าทายอ
Page 29 and 30: PrEP would be an addition to, not a
Page 31: HIVPost-Exposure Prophylaxis (PEP)
Page 36 and 37: ความเสี่ยงใ
Page 38 and 39: Definitely Potentially Not infectio
Page 40 and 41: Risk of HIV Occupational Transmissi
Page 42 and 43: Estimated Pathogen‐Specific Seroc
Page 44 and 45: Other Cofactors• Source HIV viral
Page 46 and 47: 1. First aids2. Counseling & Assess
Page 48 and 49: HIV PEP• Current multidrug regime
Page 50 and 51: Indications for Occupational PEP*So
Page 52 and 53: Recommended PEP RegimensBASIC REGIM
Page 55 and 56: Preferred regimenARV regimens forHI
Page 57 and 58: Follow-up of HCP exposed to known o
Page 59 and 60: ููุตารางที่ 1
Page 61 and 62: ตารางที่ 2.2 กา
Page 63 and 64: Recommended PEP RegimensBASIC REGIM
Page 65: ARV Regimens for HIV PEP• Raltegr
Page 68 and 69: Recommended Laboratory Evaluation f
Page 70: สรุปเรื่อง เ

Pre-Exposure Prophylaxis PrEP

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?